Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Rating)’s share price dropped 16.8% on Wednesday after HC Wainwright lowered their price target on the stock from $12.00 to $11.00. The stock traded as low as $4.55 and last traded at $4.56. Approximately 8,064 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 1,029,322 shares. The stock had previously closed at $5.48.
Insider Buying and Selling
In related news, Director Richard Klausner sold 11,100 shares of the stock in a transaction that occurred on Friday, September 23rd. The stock was sold at an average price of $6.40, for a total value of $71,040.00. Following the completion of the transaction, the director now directly owns 988,900 shares in the company, valued at $6,328,960. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 25.80% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC purchased a new position in shares of Lyell Immunopharma during the second quarter worth $38,000. Royal Bank of Canada boosted its position in shares of Lyell Immunopharma by 76.1% during the first quarter. Royal Bank of Canada now owns 9,114 shares of the company’s stock worth $46,000 after buying an additional 3,940 shares during the period. Metropolitan Life Insurance Co NY acquired a new stake in shares of Lyell Immunopharma in the first quarter valued at $50,000. Dynamic Technology Lab Private Ltd acquired a new stake in Lyell Immunopharma in the first quarter valued at $52,000. Finally, Prudential Financial Inc. acquired a new stake in Lyell Immunopharma in the first quarter valued at $55,000. 40.25% of the stock is currently owned by hedge funds and other institutional investors.
Lyell Immunopharma Price Performance
The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -5.86 and a beta of -2.01. The stock has a 50 day simple moving average of $6.86 and a two-hundred day simple moving average of $6.10.
Lyell Immunopharma (NASDAQ:LYEL – Get Rating) last posted its quarterly earnings results on Tuesday, November 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. Lyell Immunopharma had a negative return on equity of 25.87% and a negative net margin of 566.14%. Equities research analysts predict that Lyell Immunopharma, Inc. will post -1.15 EPS for the current year.
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.